ATE484505T1 - 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten - Google Patents
5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonistenInfo
- Publication number
- ATE484505T1 ATE484505T1 AT07819889T AT07819889T ATE484505T1 AT E484505 T1 ATE484505 T1 AT E484505T1 AT 07819889 T AT07819889 T AT 07819889T AT 07819889 T AT07819889 T AT 07819889T AT E484505 T1 ATE484505 T1 AT E484505T1
- Authority
- AT
- Austria
- Prior art keywords
- olderivates
- aupyrimidine
- cxcr2 antagonists
- cxcr2
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06124679 | 2006-11-23 | ||
PCT/EP2007/010098 WO2008061741A1 (en) | 2006-11-23 | 2007-11-21 | 5-sulfanylmethyl-[1,2,4] triazol[1, 5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE484505T1 true ATE484505T1 (de) | 2010-10-15 |
Family
ID=37891509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07819889T ATE484505T1 (de) | 2006-11-23 | 2007-11-21 | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten |
Country Status (13)
Country | Link |
---|---|
US (1) | US20100069407A1 (de) |
EP (1) | EP2094696B1 (de) |
JP (1) | JP2010510268A (de) |
KR (1) | KR20090080998A (de) |
CN (1) | CN101541794A (de) |
AT (1) | ATE484505T1 (de) |
AU (1) | AU2007323336A1 (de) |
BR (1) | BRPI0718947A2 (de) |
CA (1) | CA2670202A1 (de) |
DE (1) | DE602007009865D1 (de) |
MX (1) | MX2009005174A (de) |
RU (1) | RU2009123525A (de) |
WO (1) | WO2008061741A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2358716B1 (de) * | 2008-11-12 | 2016-01-06 | Merck Sharp & Dohme Corp. | Inhibitoren des fettsäurebindenden proteins (fatty acid binding protein, fabp) |
WO2011043994A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Inhibitors of fatty acid binding protein (fabp) |
WO2013122575A2 (en) * | 2012-02-14 | 2013-08-22 | Grl | Small molecule having antiviral properties |
WO2018073248A1 (en) | 2016-10-17 | 2018-04-26 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Prognosis of demyelinating diseases patients and treatment thereof |
AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
KR20210129672A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
MX2021009763A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos. |
BR112021010400A2 (pt) | 2019-02-26 | 2021-08-24 | Bayer Aktiengesellschaft | Derivados heterocíclicos bicíclicos condensados como agentes de controle de praga |
CA3165399A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
BR112022026202A2 (pt) | 2020-06-23 | 2023-01-17 | Novartis Ag | Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0208346B1 (de) * | 1985-06-11 | 1991-11-21 | Agfa-Gevaert N.V. | Diffusionsübertragungsumkehrverfahren |
DE3534651A1 (de) * | 1985-09-28 | 1987-04-09 | Bayer Ag | Triazolo-pyrimidine |
GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
JP2007537272A (ja) * | 2004-05-12 | 2007-12-20 | シェーリング コーポレイション | Cxcr1およびcxcr2ケモカインアンタゴニスト |
EP1676834A1 (de) * | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Kondensierte Bicyclische Carboxamid-Derivate zur Verwendung als CXCR2 Inhibitoren zur Behandlung von Entzündungen |
-
2007
- 2007-11-21 JP JP2009537541A patent/JP2010510268A/ja active Pending
- 2007-11-21 WO PCT/EP2007/010098 patent/WO2008061741A1/en active Application Filing
- 2007-11-21 AT AT07819889T patent/ATE484505T1/de not_active IP Right Cessation
- 2007-11-21 MX MX2009005174A patent/MX2009005174A/es not_active Application Discontinuation
- 2007-11-21 EP EP07819889A patent/EP2094696B1/de not_active Not-in-force
- 2007-11-21 US US12/514,734 patent/US20100069407A1/en not_active Abandoned
- 2007-11-21 CN CNA2007800432499A patent/CN101541794A/zh active Pending
- 2007-11-21 AU AU2007323336A patent/AU2007323336A1/en not_active Abandoned
- 2007-11-21 KR KR1020097010517A patent/KR20090080998A/ko not_active Application Discontinuation
- 2007-11-21 RU RU2009123525/04A patent/RU2009123525A/ru not_active Application Discontinuation
- 2007-11-21 DE DE602007009865T patent/DE602007009865D1/de active Active
- 2007-11-21 CA CA002670202A patent/CA2670202A1/en not_active Abandoned
- 2007-11-21 BR BRPI0718947-8A patent/BRPI0718947A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2009005174A (es) | 2009-05-25 |
EP2094696B1 (de) | 2010-10-13 |
WO2008061741A1 (en) | 2008-05-29 |
KR20090080998A (ko) | 2009-07-27 |
CA2670202A1 (en) | 2008-05-29 |
DE602007009865D1 (de) | 2010-11-25 |
US20100069407A1 (en) | 2010-03-18 |
JP2010510268A (ja) | 2010-04-02 |
BRPI0718947A2 (pt) | 2013-12-17 |
RU2009123525A (ru) | 2010-12-27 |
EP2094696A1 (de) | 2009-09-02 |
AU2007323336A1 (en) | 2008-05-29 |
CN101541794A (zh) | 2009-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE484505T1 (de) | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten | |
MX2009005363A (es) | Pirimidinas y su uso como antagonistas del receptor cxcr2. | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
ATE496051T1 (de) | Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten | |
MX2009005358A (es) | Derivados de 5-sulfanilmetil-pirazolo[1,5-a]pirimidin-7-ol como antagonistas de cxcr2. | |
MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
ATE477252T1 (de) | Substituierte diazepane als antagonisten an orexinrezeptoren | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
ATE478072T1 (de) | Spiroimidazol-derivate als ppar-modulatoren | |
NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
ATE482210T1 (de) | Oxadiazolderivate als s1p1-rezeptor-agonisten | |
ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
ATE542811T1 (de) | Piperidinylsubstituierte pyrrolidinone als inhibitoren von 11-beta- hydroxysteroiddehydrogenase 1 | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
ATE458740T1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten | |
ATE474834T1 (de) | Als agonisten des gpr38-rezeptors geeignete biarylverbindungen | |
ATE467632T1 (de) | Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors | |
ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
ATE542795T1 (de) | Benzylpiperazinderivate als motilin- rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |